A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

This study has been completed.
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
First received: September 12, 2005
Last updated: August 11, 2009
Last verified: April 2007

People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. This enzyme helps to break down and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In people with Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because alpha-galactosidase A is not present, or is present in small quantities. The build up of glycolipid levels (also referred to as "globotriaosylceramide" or "GL-3") in these tissues is thought to cause the clinical symptoms that are common to Fabry disease. Symptoms commonly appear during childhood with pain in the hands and feet. This trial is designed to evaluate the efficacy of a lower dose of Fabrazyme in patients who initially received 1.0 mg/kg every 2 weeks of Fabrazyme by investigating if the achieved clearance of glycosphingolipid deposits in the vascular endothelium of the kidney can be maintained at a lower dose.

Condition Intervention Phase
Fabry Disease
Biological: Fabrazyme (agalsidase beta)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study of Low Dose Maintenance Treatment of Fabrazyme (Recombinant Human Alpha-Galactosidase A (R-h Alpha-GAL)) Replacement Therapy in Patients With Fabry Disease

Resource links provided by NLM:

Further study details as provided by Genzyme, a Sanofi Company:

Primary Outcome Measures:
  • Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium [ Time Frame: Throughout study; 96 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium [ Time Frame: Throughout study ; 96 weeks ] [ Designated as safety issue: No ]
  • Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Throughout study; 96 weeks ] [ Designated as safety issue: No ]
  • Plasma Globotriaosylceramide (GL-3) [ Time Frame: Throughout study; 96 weeks ] [ Designated as safety issue: No ]
  • Urine Globotriaosylceramide (GL-3) [ Time Frame: Throughout study, 96 weeks ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: June 2003
Study Completion Date: March 2007
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fabrazyme
Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
Biological: Fabrazyme (agalsidase beta)
1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
Other Name: r-hαGAL


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have clinical manifestations of Fabry disease
  • All patients have to have a plasma αGAL activity of < 1.5 nmol/hr/mL or a documented leukocyte αGAL activity of < 4 nmol/hr/mg
  • Patient or patient's parent/guardian had to provide written informed consent prior to any study-related procedures being performed
  • Patients had to be male and ≥ 16 years of age

Exclusion Criteria:

  • There is evidence of renal insufficiency, as defined by serum creatinine greater than or equal to 2.2 mg/dL (194.7 μmol/L) AND/OR has an estimated glomerular filtration rate (GFR) of <80 mL/min (using the equation derived from the Modification of Diet in Renal Disease Study (MDRD))
  • Has undergone kidney transplantation or is currently on dialysis
  • Has a clinically significant organic disease or an unstable condition (with the exception of symptoms relating to Fabry disease) that in the opinion of the Investigator would preclude participation in the trial
  • Has participated in a study employing an investigational drug within 30 days of the start of this trial
  • Patients who received prior treatment with enzyme replacement therapy for Fabry disease
  • Patient was unable to comply with the requirements of the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00196716

Czech Republic
II. interní klinika 1. LF UK
Praha 2, Czech Republic, 128 02
Tartu University Clinics, Department of Internal Medicine
Tartu, Estonia, 51014
Klinika Chorob Metabolicznych, Instytut "Pomnik-Centrum Zdrowia Dziecka"
Warsaw, Poland, 04-736
Detská fakultná nemocnica Kramáre I. Interná klinika
Bratislava 37, Slovakia, 833 40
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided

Responsible Party: Medical Monitor, Genzyme Corporation
ClinicalTrials.gov Identifier: NCT00196716     History of Changes
Other Study ID Numbers: AGAL-017-01
Study First Received: September 12, 2005
Results First Received: December 5, 2008
Last Updated: August 11, 2009
Health Authority: Estonia: The State Agency of Medicine
Czech Republic: State Institute for Drug Control
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Slovakia: State Institute for Drug Control

Keywords provided by Genzyme, a Sanofi Company:
alpha Galactosidase A
rh aGAL

Additional relevant MeSH terms:
Fabry Disease
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Cardiovascular Diseases
Central Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on March 26, 2015